
EIKN Stock Forecast & Price Target
EIKN Analyst Ratings
Bulls say
Eikon Therapeutics is compelling because its proprietary single-molecule tracking platform creates a differentiated discovery engine that measures real-time target engagement in living cells, potentially improving compound selection and reducing late-stage failure risk across target classes. The near-term thesis is strengthened by in-licensed clinical assets: EIK1001 posted a 63.1% pooled ORR and 90.8% DCR in TeLuRide-005 with no Grade ≥3 CRS across 72 patients, while EIK1003 showed 90.4% relative dose intensity with paclitaxel, supporting the idea that selectivity can unlock combinations previously limited by myelosuppression. Longer term, the wholly owned EIK1005 and EIK1006 programs add unencumbered upside, and the balance sheet funds operations into 2H27, giving the company time to convert multiple upcoming readouts into value.
Bears say
Eikon Therapeutics is viewed negatively because its value depends on a clinical pipeline that remains unvalidated, with no approved products and heavy reliance on exploratory single-arm data that may not hold up in registrational studies. Its lead programs face meaningful differentiation and class-risk hurdles: EIK1001 must outperform a moving pembrolizumab-based standard of care, while EIK1003, EIK1004, and EIK1005 enter crowded spaces with signals such as modest response rates, tachycardia, and uncertainty around durability and combination benefit. Financially, the company had $531.2 million in cash and marketable securities at June 30, 2026, but guided runway only into the 2H27, leaving it exposed to dilution and milestone obligations of up to $749 million and $956 million.
This aggregate rating is based on analysts' research of Eikon Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
EIKN Analyst Forecast & Price Prediction
Start investing in EIKN
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Eikon Therapeutics Inc (EIKN) Forecast
EIKN Analyst Forecast & Price Prediction
Start investing in EIKN
Order type
Buy in
Order amount
Est. shares
0 shares